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ABSTRACT 
BACKGROUND. This cross-sectional study was performed to determine the 
reference ranges for two bone turnover markers -aminoterminal propeptide of 
type I collagen (P1NP) and C-terminal telopeptide of type I collagen (-CTX)- in 
normal adult Spanish men as measured in serum by automated methods. 
METHODS. A community-based population of 660 healthy men ≥ 50 years was 
evaluated. Fasting serum levels of P1NP, -CTX, 25-hydroxivitamin D, and 
intact parathyroid hormone were measured on the Elecsys 2010 automated 
analyzer (Roche). BMD at lumbar spine, femoral neck and total hip was 
determined by DXA.  
RESULTS. Mean age of participants was 65±9 yrs. Logarithmic transformation 
of both markers was performed to allow for normal distribution. Mid-95% ranges 
for P1NP and -CTX were 15-78 ng/ml and 0.069-0.760 ng/ml, respectively. 
Median and interquartile range of serum P1NP and -CTX were 33.5 [25.5;44.4] 
ng/ml and 0.27 [0.19;0.38] ng/ml, respectively. Mean values of P1NP 
(37.1±16.7 ng/ml) were similar to those previously described. -CTX mean 
values (0.300±0.171 ng/ml) were also similar to those quoted by the 
manufacturers in men younger than 70 yrs, but slightly lower than those 
reported in subjects older than 70 yrs. Both markers were higher among 
osteoporotic men. After excluding from the analysis those men who were found 
to have BMD below -2.5 T-score, 25OHD serum level below 30 ng/ml or serum 
PTH above 65 pg/ml, P1NP and -CTX ranges were 17-71 ng/ml and 0.070-
0.681 ng/ml, again respectively. 
CONCLUSIONS. Values obtained from this well-characterized population study 
provide reference ranges for serum automated P1NP and -CTX in normal 
Spanish adult men.  
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1. Introduction   
 
Osteoporosis is a major public health problem in the elderly that affects 
not only postmenopausal women but also men [1]. About 25-30% of 
osteoporotic fractures occur in males, and morbidity and mortality, at least after 
hip fracture, is greater in them than in women [2]. However, male osteoporosis 
has been studied less than postmenopausal osteoporosis, and was poorly 
recognized until the two last decades [1,3]. Bone mineral density (BMD) has 
proven to be as effective in men as in women in predicting the risk of fractures 
[3]. Nevertheless, other parameters related to bone strength and fracture risk, 
such as bone turnover markers (BTM) [4,5], have not been evaluated in men as 
much as BMD [6,7]. BTM reflect whole body rates of bone resorption and bone 
formation, and provide a dynamic assessment of the skeleton which may 
complement the static information given by BMD. Furthermore, BTM have 
increasingly shown to be useful in assessing the response to osteoporosis 
therapy, and helping to explain the mechanism of action of some hormonal and 
therapeutic anti- osteoporotic agents [8,9]. Reference ranges for women have 
been widely studied. However, there is a clear absence of this type of data 
regarding men.  
We have recently published the reference ranges for two BMT-
aminoterminal propeptide of type I collagen (P1NP) and C-terminal telopeptide 
of type I collagen (-CTX)-, measured by a new fully automated serum assay in 
normal Spanish postmenopausal women [10]. However, to our knowledge, 
there is no available information about normal values in Spanish men. The 
Elecsys 2010 (Roche Diagnostics, GmbH, Mannheim, Germany) equipment 
allows the determination not only of BTM but also of 25-hydroxyvitaminD3 
(25OHD) and intact parathyroid hormone (iPTH) levels, which are of high 
relevance for interpretation of BTM results. Therefore, the aim of this study was: 
i) to evaluate these automated methods to measure the serum levels of two 
BTM, P1NP and  -CTX, in order to know the reference ranges for these 
markers in Spanish adult men, and ii) to analyze their relationship with 25OHD 
and iPTH serum concentrations provided by the same equipment. BMD 
measurements were also performed, and the relationship of their results with 
BTM, 25OHD and iPTH analyzed.  
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2. Material and methods 
 
2.1. Study design and participants 
  
 The study population was set up with adult men included in the 
Camargo Cohort Study, a community-based study designed to evaluate the 
prevalence of metabolic bone diseases and the prevalence of risk factors for 
osteoporosis and fragility fractures in postmenopausal women and men older 
than 49 attended at a Primary Care Centre in Northern Spain. Participants 
were recruited while attending for medical reasons or for their regular health 
examination, whichever happened first. All participants were white, as are 
more than 95% of people in our region (Cantabria). The study was approved 
by the local Ethics Committee, and all subjects gave written informed 
consent. 
At the baseline visit, men were interviewed by investigators and all 
participants provided data regarding the risk factors for osteoporosis and 
fractures using a structured questionnaire, which included age, race, weight, 
height, body mass index (BMI), personal antecedents of fractures in 
adulthood (> 40 years), tobacco use, dairy calcium intake, alcohol 
consumption, physical exercise, number of falls in the previous year, 
presence of chronic diseases (hypertension, dyslipidemia, diabetes mellitus, 
urolithiasis, hyperthyroidism, hyperparathyroidism, chronic inflammatory 
diseases, etc); and present or past use of medications. BMI was defined as 
weight (kg) divided by squared height (m2). Tobacco smoking was assessed 
as current smoker, former smoker or never smoker. Dairy calcium 
consumption was assessed by a food frequency questionnaire. Regarding 
alcohol consumption, participants were asked how much they had consumed 
during the past 30 days and how many times they had consumed three or 
more drinks per day during this period. Habitual physical activity was 
classified as high (moving, walking and working energetically and 
participating in vigorous exercise), moderate (walking reasonable distances, 
doing light housework, shopping or its equivalent, normal activities of day-to-
day living but no appreciable exercise), and sedentary (little walking outside 
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home, or sitting in a chair most of the time). The presence of subclinical 
thyroid dysfunction was excluded by determination of serum free T4 and TSH 
levels. Full details of the Camargo cohort study have previously been 
reported [10,11]. 
Men in which the baseline assessment revealed the presence of 
diseases or treatments known to affect bone metabolism, such as 
osteoporosis, primary hyperparathyroidism, hyperthyroidism, chronic 
inflammatory diseases, serum creatinine > 151 mol/L, or treatment with 
bisphosphonates, testosterone, strontium ranelate, teriparatide, L-thyroxin or 
glucocorticoids, were excluded. Therefore, those men previously diagnosed 
and treated for osteoporosis were left out. However, those men who were 
found to be osteoporotic as a result of our BMD study were included and 
evaluated. 
2.2 Biochemical tests 
 
Fasting blood samples were collected from each participant between 
09:00 and 10:30 h. Serum was divided into 0.5-ml aliquots and stored at -
40ºC. Serum total calcium (TCa), phosphate, glucose, creatinine, albumin, 
and total alkaline phosphatase measurements were determined by standard 
automated methods in a Technicon Dax autoanalyser (Technicon 
Instruments, CO. USA). TCa measurements were corrected for albumin 
concentration (cCa) following a previously published formula [12]. Serum 
concentrations of aminoterminal propeptide of type I collagen (P1NP), C-
terminal telopeptide of type I collagen (β-CTX), 25-hydroxyvitamin D3 
(25OHD), and intact parathyroid hormone (iPTH) were determined by a fully 
automated electrochemiluminiscence system (Elecsys 2010, Roche 
Diagnostics, GmbH, Mannheim, Germany). The P1NP limit of detection was 
5 ng/ml (reference range between 19 and 100 ng/ml in Spanish 
postmenopausal women), with intra-assay and inter-assay coefficients of 
variation (CV) of 3.1% and 3.5%, respectively [10, 13]. The detection limit of 
serum β-CTX was 0.010 ng/ml, its intra-assay and inter-assay CV being 
4.2% and 4.7%, respectively, and its reference range in Spanish 
postmenopausal women 0.112-1.018 ng/ml [10,14]. The detection limit of 
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serum 25 OHD was 4 ng/ml, its intra-assay CV 5%, and its inter-assay CV 
8.5%. Regarding iPTH, the detection limit was 6 pg/ml, with a manufacturers´ 
normal range of 15-65 pg/ml. Intra-assay and inter-assay CV were 5.4% and 
5.9%, respectively [15].  
 
2.3. DXA measurements  
 
BMD was measured by DXA (Hologic QDR 4500, Bedford, MA, USA) at 
the lumbar spine (L2-L4), femoral neck, and total hip in all the 660 men who 
finally entered the study (see below). In vivo precision was 0.4-1.5% at the 
different measurement sites. Results were expressed as grams per square 
centimetre, T-score (defined as the number of standard deviations [SDs] below 
the mean value of young men), and Z-score (defined as the number of SDs 
below the mean of men of the same age). T and Z-scores were calculated using 
the NHANES III reference database for femur measurements [16]. Quality 
control was performed according to the usual standards [17].  
 
2.4. Statistical analyses 
 
Results were expressed as mean ± SD or median [interquartile range] for 
quantitative variables, and percentages of the population for qualitative 
variables. Kolmogorov-Smirnov test was used to test for normality of the data 
set distribution. As expected in adult men, serum β-CTX and P1NP were not 
distributed normally with a frequency distribution skewed toward the lowest 
values (Figure 1A and 1B). Thus, these variables underwent logarithmic 
transformation before statistical analyses. Chi-squared or Fisher’s exact test 
were performed in order to identify differences in categorical variables between 
subgroups. Mann-Whitney U-Test was used to compare BTM between the 
groups of men distributed by serum levels of iPTH, vitamin D, or osteoporosis 
status. One-way ANOVA was undertaken to assess correlation between BTM 
and age strata. Bonferroni’s test for multiple comparisons was performed when 
significant differences were found. Significance levels less than 5% were 
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considered significant. All analyses were performed using SPSS for Windows 






A total of 703 men, aged 50-92, were initially recruited. Forty-three of 
them were excluded because their baseline study revealed the presence of 
diseases or treatments known to affect bone metabolism, or even treatments 
addressed to bone metabolic diseases, including osteoporosis. The remaining 
660 men entered into the study, and their baseline characteristics are listed in 
table 1. 
 
3.2. Serum P1NP and -CTX levels 
 
Median and interquartile range of serum P1NP and -CTX in adult men 
were 33.5 [25.5;44.4] ng/ml and 0.27 [0.19;0.38] ng/ml, respectively (Table 2). 
Moreover, mean value of P1NP was 37.1 ng/ml (± 16.7) and mean value of -
CTX: 0.300 ng/ml (± 0.171). Neither of them was distributed normally, but 
skewed toward the lowest values (Fig.1A, and 1B). After log- transformation, 
data took on a normal, Gaussian distribution, and the geometric mean ± 2SD 
was used to determine the 95% range. The limits of this range were 15-78 
ng/ml for P1NP, and 0.069-0.760 ng/ml for -CTX. These values were similar to 
those obtained by our group in Spanish premenopausal women (mean P1NP: 
41.1±18.5 ng/ml, and -CTX: 0.271±0.139 ng/ml), but significantly lower than 
those observed in postmenopausal women of similar age (63±9) from our 
region (mean P1NP: 47.7 ± 19.9 ng/ml, and -CTX: 0.387 ± 0.197 ng/ml; 
(p<0.001) [10]. Thus, serum P1NP and -CTX levels in adult men were, 
respectively, 22% and 23% lower than those obtained in postmenopausal 
women.  
                                                                                     BMT in Spanish adult men 
 9 
P1NP and -CTX ranges were also calculated after excluding from the 
analysis those men who were found to have a BMD below -2.5 T-score, a 
25OHD serum level lower than 30 ng/ml or a PTH serum above 65 pg/ml. The 
corresponding values were 17-71 ng/ml and 0.070-0.681 ng/ml, quite close to 
those of the whole population, although in both cases the upper value was 
somewhat lower (about 10%). 
3.3. Changes in serum P1NP and -CTX with age 
 
Considering all men as a whole, no significant correlation between age 
and either P1NP or CTX concentrations was found. Both markers remained 
stable until the age of 80 years, although a significant rise (p=0.03) in CTX 
levels was observed in participants older than this. (Fig.1C and 1D). In fact, the 
average levels in men older than 80 years were 22% higher than those 
observed in men aged 50-60 years (Table 3).  
3.4. Comparison of BTM between subgroups 
 
P1NP and CTX values were also compared among subgroups based 
on serum 25OHD (above or below 30 ng/ml, levels generally considered to be 
the threshold for optimal vitamin D status), serum PTH (below or above 65 
pg/ml), and presence or absence of osteoporosis (defined as BMD >-2.5 T in 
lumbar spine, femoral neck or total hip). As expected, the two markers were 
higher in men with osteoporosis than in those without (p<0.01), the difference 
being 16% for P1NP and 26% for CTX.  Men with PTH levels above 65 ng/ml 
also had higher levels of both P1NP and CTX (p<0.05), and a positive 
relationship was observed between iPTH and BTM values (P1NP: r=0.135; 
p<0.001; CTX: r=0.252; p<0.001). However, no significant differences were 
seen in either marker among subgroups of men based on serum 25OHD levels 
(Table 3). Finally, we did not find any relationship between smoking habits, 
alcohol consumption, physical activity, and the other characteristics of the 
population studied (Table 1) and bone turnover markers (data not shown). 
 
3.5. BMD in adult men according to BTM values 
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The relationship between BTM and BMD was also analyzed categorizing 
men in quartiles according to bone marker levels, and comparing their BMD 
values. Adult men with P1NP and -CTX levels in the lowest quartile had a 
lumbar spine BMD 4% and 7% greater than in the highest (P1NP: 1.044±0.141 
g/cm2 vs. 1.003±0.155 g/cm2; p=0.09; -CTX: 1.060±0.153 g/cm2 vs. 
0.984±0.161 g/cm2; p<0.05). A similar pattern was seen at the femoral neck 
(P1NP: 0.833±0.124 g/cm2 vs. 0.807±0.141 g/cm2; p= 0.3; CTX: 0.849±0.112 
g/cm2 vs. 0.786±0.130 g/cm2; p<0.001) and the total hip (P1NP: 1.007±0.131 
g/cm2 vs. 0.961±0.132 g/cm2; p<0.01; -CTX: 1.021±0.124 g/cm2 vs. 
0.937±0.127 g/cm2; p<0.001). Therefore, lumbar spine and femoral neck BMD 
differences between the highest and lowest quartiles were significant when 




 We describe the reference ranges for two of the main bone markers 
(P1NP and -CTX) measured by a new automated serum assay, in 660 
Spanish adult men in which mineral metabolic disorders, bone  metabolic 
diseases (other than previously unknown osteoporosis) and treatments known 
to affect bone metabolism had been ruled out. Median value of P1NP was 33.5 
[25.5;44.4] ng/ml, and -CTX 0.27 [0.19;0.38] ng/ml.  Mean serum P1NP and -
CTX were 37.1 ng/ml (± 16.7) and 0.300 ng/ml (± 0.171). The ± 2SD range 
limits (after log-transformation) were 15-78 ng/ml for P1NP and 0.069-0.760 
ng/ml for -CTX.  
Manufactures of the automated serum P1NP assay have not yet 
developed –or at least published- their own reference values in men, so we 
cannot compare our own results with them. When compared with other 
researcher’s findings, we have found similar mean and reference values to 
those described by Garnero et al [13] in 64 men aged 40-65 years (mean ± SD: 
38.1±18.4 ng/ml; reference limits 13.9 and 85.5 ng/ml), in a study performed 
with the same methodology. Our results are also similar to those published 
more recently by Bauer et al [7] in 947 men older than 65 years who were 
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randomly selected from the Osteoporosis in Men study (MrOS), a large cohort 
of community-dwelling older men (74±6 years) from the USA (mean ± SD: 
39.0±24.9 ng/ml). Therefore, P1NP values assessed by Elecsys automated 
method appear to be similar in Caucasian men in different countries.   
In contrast, serum -CTX determined by the automated assay technique 
shows some differences between publications. Our results are very similar to 
those quoted by manufacturers in normal adult men younger than 70 years 
(0.304±0.200 ng/ml for men between 50-70 years), but lower than those 
reported in men older than 70 (0.394±0.230). In our sample, men younger and 
older than 70 show mean values of 0.296 ng/ml (±0.168) and 0.312 ng/ml 
(±0.177), respectively. Our values are also slightly lower than those reported by 
Bauer et al [7] in the subgroup of participants of the MrOS (0.41±0.21 ng/ml) 
previously referred to, aged 74±6 years. In contrast, Chen et al [18] reported a 
mean value of 0.24 ng/ml (range 0.16-0.39) in frail elderly (older than 80) men 
from Sydney, Australia. At this age, -CTX levels in our sample are 0.365 ng/ml 
(±0.162). 
We have previously published our reference range for both BTM, P1NP 
and -CTX, in women, and compared our results with those of studies 
performed in other latitudes [10]. We found a superimposable pattern: P1NP 
results are similar for all Caucasian women studied, but -CTX shows clear 
differences. 
We have no straightforward explanation for this different behaviour of the 
two BTM. Speculation could be made that bone resorption markers may be 
more influenced by the particular characteristics of participants included in each 
study, such as age, weight, smoking habits, physical activity, etc. 
On the other hand, it is of interest that serum levels of P1NP and -CTX 
in our adult males were similar compared to those previously described in 
Spanish premenopausal women (P1NP: 41.1±18.5 ng/ml; -CTX: 0.271±0.139 
ng/ml), as well as those described in young women from other countries 
[10,14,19].  
We found no change in either of the two BTM with age, apart from a late 
increase in -CTX only just after the age of 80. Szulc et al (6, 20) have reviewed 
the changes of BTM with age in men. According to them, BTM in men show 
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their lowest levels between 50 and 60 years. Thereafter, age-related increase, 
stability or decrease of bone resorption markers, have been described. 
Concerning serum bone formation markers, they remain roughly stable between 
40 and 60 years, independently of the marker studied. Over 60 years, they 
remain stable or increase slightly in cohorts including very old men (6, 21). The 
reasons for these discrepancies are not clear, but they may probably be related 
to differences in the characteristics of the participants –for instance, the 
inclusion of men with different degrees of renal function-, along with the fact that 
some of the samples studied are small in number, so that a few discordant 
participants may have a great influence in the final results. In this regard, the 
number of patients assessed in our study may be considered reassuring.     
The participants of our study were also divided into groups according to 
their serum 25OHD and iPTH levels. No significant differences were seen in 
either P1NP or -CTX between men with serum 25OHD above or below 30 
ng/ml. Consistent with our results, Chen et al [18] did not find any relation 
between bone markers and serum 25-OH vitamin D in elderly men. Regarding 
PTH stratification, men with PTH values above 65 pg/ml showed a higher level 
of P1NP (7%) and -CTX (15%). This probably reflects the increase of bone 
remodelling mediated by high levels of PTH. Finally, as we have previously 
commented on, and has been widely described for other BTM [7,22-24], both 
P1NP and -CTX were higher in osteoporotic men than in men with BMD 
greater than -2.5 T. The difference was smaller for P1NP (about 16%) than for 
-CTX (26%). Moreover, we found an inverse relationship between quartiles of 
bone markers and bone mineral density, with a difference between extreme 
quartiles of 3 to 8 %. 
Our study has some limitations. Specifically, men were recruited from a 
Primary Care Centre. In our health care system however, people of a certain 
age are asked to visit their family doctors regularly, at least once a year; 
therefore, after this period of time, all men older than 50 are expected to have 
attended the clinic. Hence our cohort may be considered representative of the 
general population. On the other hand, before being included in our cohort, men 
were carefully studied from the mineral and bone metabolism point of view, and 
excluded if any diseases or treatments known to affect this were present. 
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Among the strengths we want to emphasize, it is worth mentioning that the 
subjects of our analysis met the criteria for BMT reference individuals 
recommended by the Clinical and Laboratory Standards Institute (NCCLS) [25]. 
The sample was large enough (more than 600 men), the participants were well-
characterized, and all men provided data regarding their risk factors for 
osteoporosis and fractures. Finally, all samples were obtained at the same time 
of the day and in a fasting state. Thus factors to minimize biological variability 
were controlled. 
In conclusion, in our study we report the mean, median, and reference 
ranges for two BMT (P1NP and -CTX) from a well characterized population of 
Spanish adult men, using a new automated technique. For serum P1NP these 
values were similar to those previously described. Serum -CTX levels were 
also similar to those previously reported by the equipment manufacturers in 
males aged 50-70 years, but slightly lower than those reported for men older 
than 70 years. Both markers were higher in men with greater PTH levels and in 
men found to have osteoporosis in the course of our study. We believe that our 
reference ranges can serve as useful standards for bone turnover in adult 
males in our country. 
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P1NP: aminoterminal propeptide of type I collagen   
β-CTX:  C-terminal telopeptide of type I collagen  
25OHD: 25-hydroxivitamin D 
iPTH: intact parathyroid hormone 
BMD: bone mineral density  
LS: lumbar spine 
FN: femoral neck 
TH: total hip 
DXA: dual X-ray absorptiometry 
NHANES III: Third National Health and Nutrition Examination Survey 
BMT: bone turnover markers  
SD: standard deviation 
BMI: body mass index  
TCa: serum total calcium  
cCa : albumin-corrected serum total calcium 
CV: coefficients of variation  














                                                                                     BMT in Spanish adult men 
 16 
 Figure 1. Frequency  distribution of serum P1NP (A) and -CTX  (B) in adult 
men. Age-related changes in serum P1NP (C) and -CTX (D) in men  
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 N=660 Range 
Age (years) 65±9 50-92 
Weight  (kg) 82±11 45-121 
Height (cm) 168 ± 6 150-189 
BMI (kg/m2) 28.9± 3.4 19-41 
Waist’s perimeter (cm) 102 ± 9 74-134 
Arm spam (cm) 173 ± 9 125-197 
History of falls (last year) (%) 15 - 
Any fracture > 40 years (%) 15 - 
Physical activity 
      Sedentarism (%) 
      Moderate (%) 









Current smoking (%) 18 - 
Current alcohol consumption (%) 47 - 
Dairy calcium consumption (mg/day) 500 [300;700] 0-2000 
Calcium supplements (%) 1 - 
Vitamin D supplements (%) 1 - 
Dyslipemia (%) 32 - 
Diabetes mellitus (%) 18 - 
Urolithiasis (%) 14 - 
Table(s)
Table 2. Biochemical parameters and bone mineral density (BMD) in adult men  
 
 
Data are presented as mean ± SD or median [interquartile range]. 
  
cCa : albumin-corrected serum total calcium; P1NP: aminoterminal propeptide 
of type I collagen ; -CTX:  C-terminal telopeptide of type I collagen; 25OHD: 
25-hydroxyvitamin D; iPTH intact parathyroid hormone. BMD, LS: bone mineral 
density at the lumbar spine; BMD, FN: bone mineral density at the femoral 
neck, BMD, TH: bone mineral density at the total hip. 
 N= 660 Range 
Glucose (mmol/l) 5.22 [4.77;5.88] 3.38-15.87 
Creatinine (mol/l) 96 [86;106] 53-150 
Calcium (mmol/l) 2.40 [2.33;2.45] 2.12-2.62 
Phosphate (mmol/l) 0.99 ± 0.15 0.55-1.61 
Albumin (g/l) 45 [44;47] 30-53 
cCa (mmol/l) 2.25 [2.20;2.33] 2.10-2.55 
Alkaline phosphatase (U/l) 62 [53;74] 16-283 
25OHD (ng/ml) 24 ± 8 4-61 
iPTH (pg/ml) 52 [40;63] 14-107 
P1NP (ng/ml) 33.5 [25.5;44.4] 10.1-132.2 
-CTX (ng/ml) 0.27 [0.19;0.38] 0.02-1.31 
BMD, LS (g/cm2) 1.021 ± 0.154 0.580-1.733 
BMD, LS (T-score) -0.83 ± 1.40 -4.897-5.55 
BMD, LS (Z-score) 0.02 ± 1.46 -4.20-6.68 
BMD, FN (g/cm2) 0.817 ± 0.123 0.430-1.342 
BMD, FN (T-score) -0.82 ± 0.91 -3.71-3.02 
BMD, FN (Z-score) 0.28± 0.23 -2.33-3.92 
BMD, TH (g/cm2) 0.981 ± 0.127 0.544-1.393 
BMD, TH (T-score) -0.33 ± 0.86 -3.24-2.33 
BMD, TH (Z-score) 0.27 ± 0.89 -2.74-3.40 
 Table 3. Subgroup analysis of serum P1NP and -CTX among adult men 
according to age, serum levels of 25OHD and PTH, and the presence or 
absence of osteoporosis 




Age (years)  660   
 50-59 203 34.1 [25.9;43.9]    0.261 [0.181;0.382]* 
 60-69 267 33.1 [25.4;45.0] 0.263 [0.194;0.363]* 
 70-79 149 32.1 [24.6;43.5] 0.269 [0.185;0.386]* 
 >80   41 37.8 [29.3;48.9]    0.335 [0.238;0.475] 
25OHD  660   
 <=30 ng/ml 531 32.8 [25.3;43.5]    0.265 [0.197;0.373] 
 >30 ng/ml 129 36.8 [26.3;47.2]    0.291 [0.196;0.393] 
iPTH  660   
 <=65 pg/ml 514 32.1 [24.9;44.5]    0.261 [0.183;0.377] 
 >65 pg/ml 146 34.5 [28.0;44.1]*  0.309 [0.235;0.418]** 
Osteoporosis  660   
 Yes   88    38.9 [28.8;51.5]**   0.354 [0.235;0.471]*** 
 No 572 32.7 [25.0;43.1]   0.260 [0.182;0.366] 
 
Data are presented as median [interquartile range] 
 
*p<0.05; **p<0.01; ***p<0.001. In age subgroups, comparisons were made with 
the oldest group (>80 years). 
P1NP: aminoterminal propeptide of type I collagen; -CTX:  C-terminal 
telopeptide of type I collagen; 25OHD: 25-hydroxyvitamin D; iPTH: intact 
parathyroid hormone. 
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